EDGEWISE THERAPEUTICS INC's ticker is EWTX and the CUSIP is 28036F105. A total of 117 filers reported holding EDGEWISE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $100,676 | +1074.3% | 5,590 | +1089.4% | 0.00% | – |
| Q1 2024 | $8,573 | -95.7% | 470 | -97.4% | 0.00% | -100.0% |
| Q4 2023 | $199,513 | +474.9% | 18,237 | +201.1% | 0.00% | +100.0% |
| Q3 2023 | $34,701 | +266.1% | 6,056 | +395.2% | 0.00% | – |
| Q2 2023 | $9,478 | +8595.4% | 1,223 | -92.5% | 0.00% | -100.0% |
| Q1 2023 | $109 | +84.7% | 16,400 | +148.3% | 0.00% | +50.0% |
| Q4 2022 | $59 | -99.8% | 6,604 | +74.9% | 0.00% | +100.0% |
| Q3 2022 | $37,000 | +270.0% | 3,775 | +209.4% | 0.00% | – |
| Q2 2022 | $10,000 | -52.4% | 1,220 | -43.0% | 0.00% | – |
| Q1 2022 | $21,000 | +5.0% | 2,142 | +67.2% | 0.00% | – |
| Q4 2021 | $20,000 | +150.0% | 1,281 | +172.0% | 0.00% | – |
| Q3 2021 | $8,000 | +33.3% | 471 | +60.2% | 0.00% | – |
| Q2 2021 | $6,000 | – | 294 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,553,661 | $27,981,435 | 34.02% |
| Novo Holdings A/S | 6,344,430 | $114,263,184 | 6.63% |
| Orbimed Advisors | 15,021,721 | $270,541,195 | 5.34% |
| TCG Crossover Management, LLC | 2,272,728 | $40,931,831 | 4.27% |
| Frazier Life Sciences Management, L.P. | 3,731,067 | $67,196,517 | 3.14% |
| Cormorant Asset Management, LP | 3,006,534 | $54,147,677 | 3.13% |
| Opaleye Management Inc. | 580,000 | $10,445,800 | 2.39% |
| RA Capital Management | 8,909,091 | $160,452,729 | 2.12% |
| VR Adviser, LLC | 1,818,182 | $32,745,458 | 2.08% |
| MPM BioImpact LLC | 740,661 | $13,339,305 | 2.07% |